Key Players
Competitive Landscape
Commercial participation in the sonogenetic neuromodulation systems sector connects programmable research phased-array hardware makers with preclinical gene-therapy licensing groups and general focused-ultrasound predicate manufacturers. Forest Neurotech (Arbor Neuroscience) and Butterfly Network develop capacitive micromachined ultrasonic transducer arrays for neural interfaces, while Sonic Concepts and Verasonics supply NeuroFUS phased arrays and programmable Vantage NXT transceivers to university sonogenetics labs. Separately, general non-genetic clinical focused-ultrasound manufacturers Insightec (FDA-approved for thermal pallidothalamic tractotomy) and NaviFUS Corporation along with Cordance Medical engineer neuronavigated transcranial helmets and blood-brain barrier opening platforms. Concurrently, Salk Institute and its ARPA-H startup SonoNeu license engineered Prestin and MscL as well as TRPA1 viral constructs for preclinical validation.
Translational engineering programs in 2025 and 2026 emphasized multi-institution preclinical federal awards and neuromodulation patent consolidation as well as non-genetic transcranial headset trials. In February 2025, NaviFUS Corporation integrated Taiwanese ICT semiconductor chips with YoungTek Electronics into its non-genetic Model-101 transcranial focused ultrasound platform paired with Brainlab surgical navigation [20]. In October 2025, the Focused Ultrasound Foundation highlighted a 256-element 555 kHz transcranial ultrasound helmet developed by the University of Oxford and University College London achieving 0.25-millimeter targeting accuracy with UCL spin-out NeuroHarmonics [21]. Hardware suppliers that adapt these non-genetic transcranial arrays for preclinical AAV sonochannel studies are projected to win grant-funded laboratory tenders.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| April 2026: Salk Institute received up to USD 41.3M from ARPA-H (with Scripps, MIT, Duke, UCSD, and SonoNeu) to generate preclinical evidence needed to move sonogenetics toward clinical trials [1]. | Refractory neuropathy and movement-disorder patients need non-surgical cellular neuromodulation. | Multi-institution teams co-develop engineered sonochannel AAVs and wearable ultrasound patches. | Multi-year ARPA-H preclinical validation awards fund research ultrasound console and AAV vector kit procurement. |
| March 2026: Sonic Concepts acquired exclusive ultrasound neuromodulation patent rights for its NeuroFUS PRO line [4]. | Translational neuroscience labs require turnkey, patent-cleared transcranial phased-array hardware. | Transducer OEMs bundle multi-element 0.5-2.0 MHz arrays with optical neuronavigation. | Proprietary pulse-sequence licensing locks in academic and biotech research accounts. |
| November 2025: NaviFUS presented positive NTUH subacute stroke motor recovery clinical trial data for non-genetic neuronavigated FUS at AOCCN 2025 [8]. | Conventional post-stroke physical therapy and TMS show limited deep-circuit neuroplasticity. | Neuronavigated focused ultrasound headsets stimulate deep motor networks without microbleeds. | Outpatient neuro-rehabilitation clinics adopt frameless neuronavigated ultrasound consoles. |
| August 2026: NaviFUS published a randomized Epilepsia crossover trial of non-genetic low-intensity FUS showing 14-point monthly seizure reduction [10]. | Intravenous AAV sonogenetic vectors require transient blood-brain barrier opening to avoid craniotomy. | Handheld non-invasive focused ultrasound devices combine microbubble sonoporation with therapy. | Dual-mode BBB gene-delivery and neuromodulation consoles capture neuro-oncology and neurology suites. |
Source: Future Market Insights, Sonogenetic Neuromodulation Systems Market Report, 2026-2036.
Recent clinical and engineering milestones confirm that leading vendors pair sub-millimeter transcranial phase correction with low-threshold mechanosensitive ion-channel cassettes. Manufacturers offering integrated optical neuronavigation and non-invasive blood-brain barrier delivery are expected to lead clinical center placements.
How are key market participants positioned in the sonogenetic neuromodulation systems market?
Forest Neurotech (Arbor Neuroscience) and Butterfly Network anchor semiconductor CMUT ultrasound-on-chip brain interfaces, while Verasonics and Sonic Concepts supply programmable Vantage NXT transceivers and NeuroFUS phased arrays across global research universities. Insightec and NaviFUS Corporation along with Cordance Medical manufacture general non-genetic clinical transcranial focused-ultrasound helmets and blood-brain barrier opening systems. Meanwhile, Salk Institute and SonoNeu / SoftSonics Ventures control core Prestin and MscL sonogenetic patents undergoing ARPA-H preclinical validation.
What qualification or purchasing requirements matter most to prospective buyers?
Translational neurosurgery directors require independent acoustic hydrophone verification showing peak negative pressures between 0.1 and 0.6 MPa and a Mechanical Index below 0.71 to guarantee zero thermal or cavitation injury. Hospital physicists also demand automated 3D CBCT or CT skull-bone phase-aberration correction software that locks the acoustic focus within 1.5 millimeters of the target nucleus. Furthermore, institutional biosafety committees require high-purity AAV9 vector lots verified free of empty capsids.
Which product or application capabilities distinguish the leading companies?
Verasonics stands out through its open-architecture Vantage NXT software beamformer capable of interleaved long-pulse neuromodulation and ultrafast plane-wave Doppler imaging. Sonic Concepts differentiates via its multi-element NeuroFUS PRO transcranial transducers and exclusive neuromodulation patent portfolio, whereas Forest Neurotech and Butterfly Network excel in miniaturized CMUT epidural and wearable arrays. NaviFUS and Cordance Medical distinguish themselves through frameless optical neuronavigation and outpatient blood-brain barrier sonoporation.
How does geographic reach differ among the key market players?
Verasonics and Sonic Concepts along with Butterfly Network and Insightec maintain direct sales and engineering support across North America and Western Europe as well as East Asia. Forest Neurotech and Cordance Medical along with Salk Institute / SonoNeu concentrate preclinical translational operations across United States ARPA-H and NIH research hubs. Meanwhile, NaviFUS Corporation anchors clinical focused-ultrasound hospital networks in Taiwan and Japan while expanding regulatory partnerships in the United States and Australia.
Representative Company Overview
| Company | Positioning | Verified Development |
|---|---|---|
| Forest Neurotech (Arbor Neuroscience) | Focused Research Organization (now Arbor Neuroscience) developing ultrasound brain-computer interfaces. | Partnered with Butterfly Network under a 5-year USD 20M Ultrasound-on-Chip neural interface agreement [17]. |
| Butterfly Network, Inc. | Semiconductor Ultrasound-on-Chip pioneer supplying MEMS/CMUT transducer arrays for neural interfaces. | Co-develops implanted and wearable whole-brain ultrasonic neural interfaces with Forest Neurotech [17]. |
| Cordance Medical | Mountain View developer of the FDA Breakthrough-designated NeuroAccess non-invasive BBB platform. | Develops non-invasive focused ultrasound blood-brain barrier opening and liquid-biopsy neurology systems. |
| Sonic Concepts, Inc. | Bothell-based manufacturer of NeuroFUS PRO transcranial phased-array transducers and systems. | Holds exclusive global perpetual license to ASU/IST ultrasound neuromodulation patents for NeuroFUS research systems [4]. |
| Insightec Ltd. | General clinical focused-ultrasound manufacturer operating the non-genetic Exablate Neuro thermal ablation helmet across 197 centers. | Received FDA approval in July 2025 for staged bilateral pallidothalamic tractotomy in Parkinson's disease [18]. |
| NaviFUS Corporation | Taipei-based developer of frameless neuronavigation-guided non-genetic transcranial focused ultrasound systems and BBB opening platforms. | Published randomized Epilepsia trial in August 2026 [10], presented AOCCN stroke data [8], and integrated Taiwan ICT chips [20]. |
| Salk Institute / SoftSonics Ventures | Foundational discoverer of Prestin and TRPA1 sonogenetics and lead institution for ARPA-H translation. | Awarded up to USD 41.3 million by ARPA-H in April 2026 (with startup SonoNeu) to build preclinical evidence required to move sonogenetics into future clinical trials [1]. |
| Verasonics, Inc. | Kirkland-based leader in programmable Vantage and Vantage NXT research ultrasound systems. | Profiled across 4,600+ scientific citations in March 2025 [7] and updated its Extended Transmit Option in August 2026 [19]. |
Research Methodology
The sonogenetic neuromodulation systems market assessment was conducted using a combination of primary research, secondary research, and data triangulation to validate market size, segmentation shares, country-level growth rates, and competitive positioning.
